国家医保局近日公布了2024年国家医保药品目录调整的初步形式审查结果，共有440个药品通过了审查。这些药品在满足申报条件并通过形式审查后，将有机会参与后续的专家评审和谈判竞价，最终可能被纳入国家医保药品目录。
形式审查是确保药品申报资料的完整性和规范性，以及药品是否符合当年的申报条件的重要步骤。通过审查的药品只是具备了参与目录调整的资格，并不意味着它们已经进入医保目录。
与去年相比，今年申报药品的数量有所增加，显示了药品企业和市场对医保目录调整的关注和参与热情。国家医保局强调，始终坚持以“保基本”为原则，坚持稳健可持续，注重医保基金和参保群众承受能力，通过谈判等方式降低药品价格，并注重提升药品的可及性和公平性。
对于一些价格昂贵的药品也通过了初步形式审查的情况，国家医保局表示，这并不意味着这些药品一定会被纳入医保目录。医保目录的调整将综合考虑药品的临床价值、价格以及医保基金的承受能力等因素，以确保医保基金的可持续性，同时满足人民群众的基本医疗需求。
此次公布的初步形式审查结果，是国家医保药品目录调整工作的重要一步，后续将通过专家评审和谈判竞价等环节，最终确定哪些药品能够被纳入国家医保药品目录，为广大参保群众提供更多的医疗保障选择。
英语如下：
News Title: 440 Drugs Cleared for Health Insurance Negotiations After Initial Review
Keywords: Health Insurance Drugs, Initial Review, 440
News Content: The National Health Insurance Administration (NHIA) recently announced the preliminary form review results for the 2024 National Health Insurance Drug Catalogue adjustment. A total of 440 drugs have passed the review. These drugs, having met the application conditions and passed the form review, will have the opportunity to participate in the subsequent expert review and negotiation bidding, potentially being included in the National Health Insurance Drug Catalogue.
The form review is an important step to ensure the completeness and standardization of the drug application materials, as well as to confirm whether the drugs meet the application criteria for that year. Passing the review only grants the drugs the qualification to participate in the catalog adjustment; it does not mean they have been included in the health insurance catalog.
Compared to last year, there was an increase in the number of drugs submitted for application, indicating greater attention and participation from pharmaceutical companies and the market in the health insurance catalog adjustment. The NHIA emphasizes that it adheres to the principle of “ensuring basic needs,” maintaining stability and sustainability, and paying attention to the bearing capacity of health insurance funds and the insured population, reducing drug prices through negotiations and focusing on enhancing the accessibility and fairness of drugs.
Regarding the situation where expensive drugs have also passed the preliminary form review, the NHIA stated that this does not mean these drugs will definitely be included in the health insurance catalog. The adjustment of the drug catalog will take into account various factors such as the clinical value of the drugs, their prices, and the bearing capacity of the health insurance fund to ensure the sustainability of the fund while meeting the basic medical needs of the people.
The announcement of the preliminary form review results is an important step in the adjustment of the National Health Insurance Drug Catalogue, with the subsequent expert review and negotiation bidding stages determining which drugs will ultimately be included in the National Health Insurance Drug Catalogue, providing more medical security options for the vast number of insured individuals.
【来源】http://www.chinanews.com/life/2024/08-07/10265157.shtml
Views: 1